Transgene to start clinical development of lead myvac TM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

information fournie par Boursorama •05/03/2019 à 17:45

Transgene to start clinical development of lead myvac TM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

o TG4050 is a neoantigen therapeutic vaccine developed for individual patients, based on the specific mutations identified in the patient's own tumor
o Two clinical trials in ovarian cancer and head and neck cancer patients will start in 2019
o Both studies will be co-funded by Transgene and NEC


Strasbourg, France, March 05, 2019 - 5:45 pm CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces its decision to initiate clinical developments of its lead myvac TM candidate, TG4050, and the finalization of its collaboration agreement with NEC. This product is designed and manufactured by Transgene using its proprietary platform myvac TM (*1) and integrating neoantigens selected by NEC's Neoantigen Prediction System (*2).
.../...